SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently under intense scrutiny as it approaches its earnings release, with investors weighing the company's 'Win Now' turnaround strategy against ongoing concerns regarding market share, tariff-driven costs, and performance in the China market. While some in the community see the current multi-year lows as a compelling buying opportunity, others remain skeptical, citing continued bearish price action and poor sentiment as indicators that the stock may face further downside before a meaningful recovery.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the company's long-awaited 10-K filing and Q4 earnings call, with community sentiment fueled by debt reduction progress and the strong performance of key holdings like Applied Digital and BW. The community is actively debating the potential for a valuation re-rating and a short squeeze, balancing caution over compliance deadlines against bullish conviction in the firm's turnaround strategy.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility driven by concerns over new import tariffs, leading to a sharp sell-off as investors weigh the impact on the company's heavily China-dependent supply chain. While some traders are betting on a short squeeze or a potential rebound if tariffs are eased, the community remains deeply divided, with many debating whether the stock's recent decline represents an oversold buying opportunity or a deeper fundamental issue.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing a significant boost in sentiment following the official commercial launch of YARTEMLEA, as investors are actively tracking shipping updates and initial hospital adoption to validate the revenue potential of the drug. Community discourse is heavily focused on the company's ability to maintain a strong cash position while managing short interest, with many hoping that the confirmation of sales will finally force a break from recent price consolidation and attract institutional capital.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is currently in focus as investors weigh the company's transition from research and development to commercial execution amid increased financial transparency. While some community members remain skeptical regarding the timing of revenue and past management actions, others are actively analyzing recent capital raises and potential ecosystem integrations to gauge the company's position within the rapidly evolving AI photonics landscape.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as its community actively rallies behind the ticker to push for mass adoption and increased visibility across social channels. Investors are focused on leveraging the project's long-standing presence and unique engagement style to drive further momentum for the token.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is capturing intense investor attention as participants digest new Phase 3 data for sonelokimab, while retail traders and institutional interests remain fixated on the potential for a high-value acquisition by major pharmaceutical players. The community is actively debating the drug's 'best-in-class' potential, with discussions heavily focused on clinical trial metrics and the persistent tension between long-term bullish sentiment and ongoing concerns regarding market manipulation.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently a focal point for retail traders who are closely monitoring its high short interest and institutional activity as a potential catalyst for a squeeze. While the community remains divided over the company's long-term business model and recent financial performance, the stock's recent volatility has intensified discussions regarding its technical breakout levels and speculative upside.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending after the FDA approved EMPAVELI for the treatment of rare kidney diseases, marking a significant milestone that investors hope will catalyze long-term growth. The community is actively discussing whether this label expansion de-risks the company as a potential buyout target while closely monitoring upcoming earnings for signs of sustained commercial execution.

nCino, Inc. engages in the provision of cloud-based software applications for financial institutions in the United States and internationally. Its nCino Bank Operating System, a tenant cloud platform, digitizes, automates, and streamlines complex processes and workflow, and utilizes data analytics and artificial intelligence and machine learning (AI/ML) to enable financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposit and other accounts, and manage regulatory compliance. The firm's nCino IQ is an application suite that utilizes data analytics and AI/ML to provide its customers with automation and insights into their operations, such as tools for analyzing, measuring, and managing credit risk, as well as to enhance their ability to comply with regulatory requirements. The company was founded by Pierre Naudé in 2011 and is headquartered in Wilmington, NC.

Ncino Inc.

nCino is trending following the announcement of a $100 million accelerated share repurchase program, sparking community discussion about the company's capital allocation strategy and long-term growth potential. Investors are closely monitoring the stock as it navigates a broader fintech sector transition, with debates centering on its ability to leverage AI-driven banking solutions and maintain market share.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
